Thursday, April 4, 2024 
6:30 PM - 7:30 PM ET
Despite meaningful improvements in treatment for hemophilia B, there remains a need for new therapeutic options that will reduce bleeds, reduce or eliminate the need for routine factor IX prophylaxis, and provide long-term benefits of sustained factor IX activity levels. The first ever FDA-approved gene therapy for hemophilia B is designed to reduce the burden of disease on patients� lives by addressing these unmet needs.
Join our educational product theater session as a team of hemophilia B experts discuss the clinical data and the patient and HCP journey towards treatment as well as share their clinical experiences with gene therapy for hemophilia B.
Continuing education credits will not be offered for this program.
This Content is Locked.